Literature DB >> 29329145

Orthopaedic Management of Leg-length Discrepancy in Proteus Syndrome: A Case Series.

Molly M Crenshaw1, Cara G Goerlich2, Lauren E Ivey1, Julie C Sapp1, Kim M Keppler-Noreuil1, Allison C Scott3, Leslie G Biesecker1, Laura L Tosi2.   

Abstract

INTRODUCTION: Proteus syndrome (PS) is a rare mosaic disorder comprising asymmetric bony and soft tissue overgrowth leading to significant morbidity. Placement of growth inhibition hardware with subsequent epiphyseal arrest improves leg-length and angular deformities in pediatric patients without PS. The purpose of this study was to review the surgical approach and present outcomes, complications, and recommendations in 8 patients with PS and leg-length discrepancy (LLD).
METHODS: We conducted a retrospective chart review of 8 patients with PS whose primary reason for surgery was LLD. Patients were eligible if they met clinical diagnostic criteria for PS and if the National Institutes of Health team performed at least 1 of their surgical interventions between 2005 and 2015. Surgical techniques included growth inhibition, with tension band plates, applied ≥1 times, and epiphyseal arrest.
RESULTS: Eight patients, followed for an average of 4.6 years (range, 1.0 to 7.1 y) after the index procedure, were included in this analysis. Average age at first LLD surgery was 9.4 years (range, 6.1 to 13.6 y); the average LLD was 3.4 cm (range, 0.4 to 7.0 cm) at presentation, and 5.0 cm (range, 1.8 to 10.0 cm) at the time of the first LLD surgery. Participants underwent 23 total surgeries (range, 1 to 5 per patient) and 7 patients have completed surgical intervention. For the 7 patients who did not require overcorrection the average LLD at the last clinical encounter was 2.6 cm (range, 0.6 to 7.2 cm). We encountered 2 complications: 2 patients developed mild knee valgus, which responded to standard guided growth techniques.
CONCLUSIONS: This case series suggests that growth inhibition and epiphyseal arrest in children with PS can reduce LLD with few complications. Careful monitoring, rapid mobilization, deep venous thrombosis prophylaxis, and sequential compression devices were also integral elements of our surgical protocol. LEVEL OF EVIDENCE: Level IV.

Entities:  

Mesh:

Year:  2018        PMID: 29329145     DOI: 10.1097/BPO.0000000000001121

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  5 in total

1.  Allelic heterogeneity of Proteus syndrome.

Authors:  Anna Buser; Marjorie J Lindhurst; Hannah C Kondolf; Miranda R Yourick; Kim M Keppler-Noreuil; Julie C Sapp; Leslie G Biesecker
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-06-12

2.  Prophylactic anticoagulation of individuals with Proteus syndrome and COVID-19.

Authors:  Christopher A Ours; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2020-09-10       Impact factor: 2.578

3.  Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome.

Authors:  Christopher A Ours; Julie C Sapp; Mia B Hodges; Allison J de Moya; Leslie G Biesecker
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

4.  Development of the Clinical Gestalt Assessment: a visual clinical global impression scale for Proteus syndrome.

Authors:  Christopher A Ours; Mia B Hodges; Neal Oden; Julie C Sapp; Leslie G Biesecker
Journal:  Orphanet J Rare Dis       Date:  2022-04-23       Impact factor: 4.303

5.  Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.

Authors:  Kim M Keppler-Noreuil; Jay Lozier; Neal Oden; Anjali Taneja; Jasmine Burton-Akright; Julie C Sapp; Leslie G Biesecker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-09-06       Impact factor: 3.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.